Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

Refractory Malignant Solid Neoplasm Clinical Trial

— Amaretto  

Official title:

An Open, Single-center, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of mRNA CAR-mesothelin T Cells in Patients With Advanced Refractory Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04981691
• Other study ID #: Amaretto
• Status: Recruiting
• Phase: Phase 1
• Start date: October 1, 2021
• Est. completion date: July 9, 2022

Study information

• Verified date: September 2021
• Source: Ruijin Hospital
• Contact: Jun Zhang, MD, PhD
• Phone: 0086-13818332497
• Email: junzhang10977[@]sjtu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

Description:

This phase I study is being conducted to establish safety, pharmacokinetics, and preliminary efficacy of intravenous (IV) mRNA electroporated fully-humanized anti-MESO re-directed autologous T cell administration in patients with chemotherapy-refractory metastatic solid tumors. The study will adopt the "3+3" dose escalation design exploring two doses of 1×109 and 3×109. The administration is planned to infuse 3 times a week for 2 consecutive weeks. • The subjects will receive a total dose of 1x109 RNA transduced anti-MESO CAR-T cells in the first week, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. If there is no obvious dose-limiting toxicity (DLT) after the first week of infusion, three times consecutive infusions of 1x109 anti-MESO CAR-T cells each time is planned in the second week. Each subject needs to be observed for at least 2 weeks (14 days) after completing the last infusion. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of anti-MESO CAR-T cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: July 9, 2022
• Est. primary completion date: January 9, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Ability to understand and the willingness to provide written informed consent.

2. Advanced pancreatic cancer, ovarian cancer, malignant mesothelioma, gastric cancer, bowel cancer, etc., diagnosed by histopathological or cytological examination, but not limited to subjects with various advanced solid tumors.

3. IHC test showed Mesothelin positive expression at least 1+ in tumor tissue

4. Age no less than 18 years.

5. Life expectancy greater than 3 months.

6. According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, there must be measurable lesions.

7. Evidence of metastatic disease and failure of at least 1 prior chemotherapy for metastatic disease. During the last treatment or after the treatment, the disease progressed and was confirmed (the investigator judged according to the RECIST 1.1 standard).

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 during the screening period and before apheresis.

9. Adequate liver/bone marrow function.

10. Female subjects must meet the following conditions: infertility or fertility and use high-efficiency contraceptive measures.

11. Male subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last study treatment infusion.

Exclusion Criteria:

1. Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to entry into the study.

2. Received any anticancer medication in the 2 weeks prior to receiving their first dose of study treatment, including but not limited to surgery, systemic chemotherapy, radiotherapy, intervention, etc.

3. Uncontrolled thyroid dysfunction (serum thyroid hormone determination TT4, TT3, FT3, FT4, and serum thyroid-stimulating hormone TSH) are not suitable for enrolling in the study;

4. Pregnant or breastfeeding female, or not willing to take contraception measures during the study.

5. Any uncontrollable active infection, including but not limited to active tuberculosis; HBV infection (including HBsAg positive, or HBcAb positive and HBV DNA positive); HIV, syphilis, hepatitis C positive or suffering from other fatal viruses, Bacterial disease

6. Administrated with steroids (5 mg/day or more dexamethasone, or equivalent hormone drugs) within the past two weeks;

7. Other uncontrolled diseases may cause abnormal death of the patient;

8. Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks.

9. Previously allergic to immunotherapy, tocilizumab, cyclophosphamide, fludarabine, and other related drugs, previous history of severe allergies, to research product excipients (such as human serum albumin, DMSO, and dextran 40 ); people who have a history of penicillin allergy and have a positive skin test at the time of screening.

10. Congestive heart failure, uncontrolled cardiac arrhythmia, etc.

11. Uncontrollable massive ascites, that cannot be drained by standard methods;

12. Intestinal obstruction or CT suggesting omental cake-like peritoneal metastasis, or repeated uncontrollable incomplete intestinal obstruction.

13. Have received any genetic engineering modified T cell therapy (including CAR T, TCR T cell).

14. Uncontrolled brain metastasis or mental illness.

15. Suffered from other uncured malignant tumors within the past 3 years or at the same time.

16. The blood oxygen saturation =95% at the time of screening and before apheresis.

17. Can't be followed up or obey protocol.

18. The investigator believes that it is not appropriate to participate in the trial.

Related Conditions & MeSH terms

• Refractory Malignant Solid Neoplasm

Intervention

Biological:
• anti-MESO CAR T cells
Autologous genetically modified anti-MESO CAR T cells

Locations

Country	Name	City	State
China	Department of Oncology, Ruijin Hospital	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Ruijin Hospital	UTC Therapeutics Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	mesothelin expression and efficacy	Immunohistochemical method to detect the expression of mesothelin, CT or magnetic resonance image(MRI) evaluation efficacy, statistical method (SPSS 24.0) to assess the correlation between mesothelin expression level and efficacy	12 weeks after the last infusion
Primary	TEAEs	Incidence of Treatment Emergent Adverse Event	4 weeks after the last infusion
Primary	TRAEs	Incidence of Treatment Related Adverse Events	4 weeks after the last infusion
Primary	SIAEs and SAEs	Incidence of AEs of Special Interest and Serious Adverse Events	4 weeks after the last infusion
Primary	DLTs	Incidence of dose-limiting toxicities	4 weeks after the last infusion
Secondary	TEAEs,TRAEs, SIAEs and SAEs	Incidence of Treatment Emergent Adverse Event, Treatment Related adverse events, AEs of special interest and serious adverse events	12 weeks after the last infusion
Secondary	ORR by IR	Objective response rate based on investigator's evaluation	12 weeks after the last infusion
Secondary	ORR by IRC	ORR based on independent review committee evaluation	12 weeks after the last infusion
Secondary	DCR by IR	Disease control rate based on the investigator's evaluation	12 weeks after the last infusion
Secondary	DCR by IRC	DCR based on IRC evaluation	12 weeks after the last infusion
Secondary	DOR by IR	Duration of Remission based on the investigator's evaluation	12 weeks after the last infusion
Secondary	TTR by IR	Time to remission based on the investigator's evaluation	12 weeks after the last infusion
Secondary	PFS by IR	Progression-free survival (PFS) based on the investigator's evaluation	24 weeks after the last infusion
Secondary	PFS by IRC	PFS based on IRC evaluation	24 weeks after the last infusion
Secondary	OS	Overall survival	52 weeks after the last infusion
Secondary	QOL	According to the EUROPEAN Organization for Research and Treatment of Cancer, Eortc, Quality of Life QuestionNare-Core 3, QOQ-C30), ERTC QLQ-C30, evaluated subject's quality of life.	12 weeks after the last infusion
Secondary	Cmax	the highest concentration (Cmax) of anti-human MESO T cells in the peripheral blood after CAR T cell infusion	4 weeks after the last infusion
Secondary	AUC	the area under the curve of 28 days of anti-human MESO T cells in the peripheral blood after CAR T cell infusion	4 weeks after the last infusion
Secondary	HACA	Positive rate of Human Anti-CAR Antibodies after CAR T cell infusion	4 weeks after the last infusion